European Commission Approved Celltrion Healthcare’s Bevacizumab Biosimilar

The European Commission (EC) has approved Vegzelma (CT-P16), a biosimilar to bevacizumab referencing Avastin, developed by Celltrion Healthcare. Celltrion Healthcare has announced that, the European Commission (EC) has approved Vegzelma (CT-P16), its biosimilar to be bevacizumab, referencing the Avastin approved by the European Union (EU). This European approval covers the use of Vegzelma in the […]

Continue Reading